Study of type 1 interferonopathies in Europe
Part of Brain & nervous system, Genetic & congenital, Immune system & allergy clinical trials.
This study looks at people with a confirmed type 1 interferonopathy, a rare immune condition caused by a gene change. It aims to learn more about how the condition progresses over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test that shows you have a type 1 interferonopathy.
- You must be enrolled in health insurance or a similar national health program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic diseases that affect the immune system and the brain. It aims to better understand these conditions by comparing patients, their relatives, and healthy controls.
This study follows people with difficult-to-treat inflammatory or autoimmune diseases to see how safe and effective newer treatments (called immunomodulators) are. It is observational, meaning the researchers will just watch and record what happens during your regular care.
This study aims to understand the immune system in people who have immune problems or whose immune-related diseases are not helped by standard treatments. It may lead to better ways to diagnose and treat these conditions.
This study looks at people with autoimmune hepatitis (an immune system condition that attacks the liver). It aims to learn more about the disease by following patients who live in Switzerland.
This study looks at a protein called type I interferon, which is often too high in people with autoimmune diseases. The goal is to better understand how it relates to these conditions, which may help improve future treatments.
This study tests an experimental drug (IMSB301) for people with rare genetic conditions that cause too much type 1 interferon activity (a part of the immune system). The goal is to see if the drug is safe and can help reduce symptoms.
Hear when a new Genetic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.